Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR T-Cell therapy targets tough blood cancers

NCT ID NCT07239323

Recruiting now Disease control Sponsor: Chongqing Precision Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new type of CAR T-cell therapy for adults with blood cancers like leukemia, lymphoma, and multiple myeloma that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goals are to find a safe dose and see if it can shrink tumors, though long-term control is not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell childhood acute lymphoblastic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma Burkitt lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL NON-HODGKIN'S LYMPHOMA MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

    RECRUITING

    Kunming, Yunnan, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••